The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $5.41

Today's change0.00 0.00%
Updated December 7 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $5.41

Today's change0.00 0.00%
Updated December 7 4:00 PM -5GMT. Delayed by at least 15 minutes.

Merrimack Pharmaceuticals Inc closed at (U.S.)$5.41.

Over the last five days, shares have lost 1.81% and are down 31.52% for the last year to date. This security has underperformed the S&P 500 by 41.85% during the last year.

Key company metrics

  • Open(U.S.) $5.45
  • Previous close(U.S.) $5.41
  • High(U.S.) $5.60
  • Low(U.S.) $5.25
  • Bid / Ask(U.S.) $5.30 / (U.S.) $5.44
  • YTD % change-31.52%
  • Volume1,799,938
  • Average volume (10-day)2,168,240
  • Average volume (1-month)2,894,294
  • Average volume (3-month)2,925,153
  • 52-week range(U.S.) $4.39 to (U.S.) $9.02
  • Beta2.00
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.38
Updated December 7 4:00 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-160.80%

Although this company's net profit margin is negative, it is above the industry average and implies that Merrimack Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.74%Sector:HealthcareIndustry:Biotechnology

Latest Company News

    No News Results.

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue28342121
Total other revenue--------
Total revenue28342121
Gross profit27322121
Total cost of revenue1210
Total operating expense52645164
Selling / general / administrative18211819
Research & development32413345
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)1------
Other operating expenses, total--------
Operating income-24-30-30-43
Interest income (expense), net non-operating-7-21-9-6
Gain (loss) on sale of assets--------
Other--------
Income before tax-30-51-39-48
Income after tax-30-51-39-48
Income tax, total--------
Net income-30-51-38-48
Total adjustments to net income--------
Net income before extra. items-30-51-38-48
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-30-51-38-48
Inc. avail. to common incl. extra. items-30-51-38-48
Diluted net income-30-51-38-48
Dilution adjustment0----0
Diluted weighted average shares129126116116
Diluted EPS excluding extraordinary itemsvalue per share-0.23-0.40-0.33-0.41
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.23-0.40-0.33-0.41